Novo Nordisk sues Eli Lilly over GLP-1 advertising claims
The Danish drugmaker has filed legal proceedings alleging that Eli Lilly’s marketing for its weight-loss and diabetes medications is misleading, according to reports from CNBC.
Novo Nordisk has initiated legal action against Eli Lilly, alleging that the American drugmaker’s advertising for GLP-1 medications is misleading. The lawsuit, first reported by CNBC on 21 July 2026, marks a significant escalation in the commercial rivalry between the two firms in the high-stakes market for diabetes and weight management treatments.
In its filing, Novo Nordisk characterised the rival’s promotional campaigns as deceptive. The Danish company is seeking a permanent injunction to halt the advertisements immediately. Beyond stopping the current marketing efforts, Novo Nordisk has specifically requested that the court order Eli Lilly to issue corrective advertising to address what it describes as false or misleading claims.
GLP-1 drugs have become a focal point for capital markets and pharmaceutical investors, with Novo Nordisk and Eli Lilly emerging as the dominant competitors in this therapeutic class. The litigation underscores the intensity of the competition as both companies vie for market share in treatments used for diabetes and obesity.
The source material does not detail the specific content of the advertisements that Novo Nordisk finds objectionable. Furthermore, the legal jurisdiction or the specific court where the action was filed has not been disclosed in the available reports.
As a newly filed action, the outcome of the dispute remains uncertain. The provided information does not include a response or statement from Eli Lilly regarding the allegations. The term "deceptive" is used to reflect Novo Nordisk’s specific legal allegation rather than an established judicial finding.
